Tie1 contributes to the development of ovarian hyperstimulation syndrome under the regulation of EGR1 in granulosa cells
1
조회
0
다운로드
0
인용
0
참고문헌
초록
The expression of tyrosine kinase with immunoglobulin-like and epidermal growth factor-like domains 1 (Tie1), a transmembrane protein expressed almost exclusively by endothelial cells, has been reported in granulosa cells. However, its significance in ovarian hyperstimulation syndrome (OHSS), which can occur after the injection of gonadotropins in infertile women undergoing controlled ovarian stimulation, is unknown. Here, we report significantly increased Tie1 and vascular endothelial growth factor (VEGF) expression in cultured granulosa cells from OHSS patients, as well as ovaries from rats with experimentally established OHSS, compared to controls, with the levels of both proteins also increasing in granulosa and SVOG cells (a nontumorigenic human granulosa-lutein cell line) treated with an acute dose of human chorionic gonadotropin (hCG). Tie1 silencing abolished the hCG-induced VEGF level in SVOG cells and attenuated the progression of OHSS in rats, as determined by histological analysis. Further studies in SVOG cells revealed that the hCG-induced upregulation of Tie1 expression involved the phosphoinositide 3-kinase/protein kinase B signaling pathway. We also report that early growth response protein 1 (EGR1), whose expression was also upregulated by hCG, bound directly to the Tie1 promoter and activated its transcription. Taken together, our results indicate that Tie1 may be a therapeutic target in cases of moderate-to-severe OHSS. Further studies are needed to address its clinical relevance.
Abstract
The expression of tyrosine kinase with immunoglobulin-like and epidermal growth factor-like domains 1 (Tie1), a transmembrane protein expressed almost exclusively by endothelial cells, has been reported in granulosa cells. However, its significance in ovarian hyperstimulation syndrome (OHSS), which can occur after the injection of gonadotropins in infertile women undergoing controlled ovarian stimulation, is unknown. Here, we report significantly increased Tie1 and vascular endothelial growth factor (VEGF) expression in cultured granulosa cells from OHSS patients, as well as ovaries from rats with experimentally established OHSS, compared to controls, with the levels of both proteins also increasing in granulosa and SVOG cells (a nontumorigenic human granulosa-lutein cell line) treated with an acute dose of human chorionic gonadotropin (hCG). Tie1 silencing abolished the hCG-induced VEGF level in SVOG cells and attenuated the progression of OHSS in rats, as determined by histological analysis. Further studies in SVOG cells revealed that the hCG-induced upregulation of Tie1 expression involved the phosphoinositide 3-kinase/protein kinase B signaling pathway. We also report that early growth response protein 1 (EGR1), whose expression was also upregulated by hCG, bound directly to the Tie1 promoter and activated its transcription. Taken together, our results indicate that Tie1 may be a therapeutic target in cases of moderate-to-severe OHSS. Further studies are needed to address its clinical relevance.
참고문헌 (45)
- Smitz, J., "Influence of human chorionic gonadotrophin during ovarian stimulation : an overview", Reprod. Biol. Endocrinol, 18, pp.80~ (2020)
- Delvigne, A., "Epidemiology and prevention of ovarian hyperstimulation syndrome(OHSS) : a review", Hum. Reprod. Update, 8, pp.559~577 (2002)
- Nastri, C. O., "Ovarian hyperstimulation syndrome : pathophysiology, staging, prediction and prevention", Ultrasound Obstet. Gynecol, 45, pp.377~393 (2015)
- Nastri, C. O., "Ovarian hyperstimulation syndrome : pathophysiology and prevention", J. Assist. Reprod. Genet, 27, pp.121~128 (2010)
- Aboulghar, M., "Symposium: update on prediction and management of OHSS. Prevention of OHSS", Reprod. Biomed. Online, 19, pp.33~42 (2009)
- Delbaere, A., "New insights into the pathophysiology of ovarian hyperstimulation syndrome. What makes the difference between spontaneous and iatrogenic syndrome?", Hum. Reprod, 19, pp.486~489 (2004)
- Rizk, B., "Symposium: update on prediction and management of OHSS. Genetics of ovarian hyperstimulation syndrome", Reprod. Biomed. Online, 19, pp.14~27 (2009)
- Sturtzel, C., "Endothelial cells", Adv. Exp. Med. Biol, 1003, pp.71~91 (2017)
- Kruger-Genge, A., "Vascular endothelial cell biology: an update", Int. J. Mol. Sci, 20, pp.4411~ (2019)
- Clauss, M., "Molecular biology of the VEGF and the VEGF receptor family", Semin. Thromb. Hemost, 26, pp.561~569 (2000)
- Shah, D. K., "Thiazolidinediones decrease vascular endothelial growth factor (VEGF) production by human luteinized granulosa cells in vitro", Fertil. Steril, 93, pp.2042~2047 (2010)
- Aboulghar, M. A., "Elevated levels of interleukin-2, soluble interleukin-2 receptor alpha, interleukin-6, soluble interleukin-6 receptor and vascular endothelial growth factor in serum and ascitic fluid of patients with severe ovarian hyperstimulation syndrome", Eur. J. Obstet. Gynecol. Reprod. Biol, 87, pp.81~85 (1999)
- Wang, T. H., "Human chorionic gonadotropin-induced ovarian hyperstimulation syndrome is associated with up-regulation of vascular endothelial growth factor", J. Clin. Endocrinol. Metab, 87, pp.3300~3308 (2002)
- Gomez, R., "Low-dose dopamine agonist administration blocks vascular endothelial growth factor (VEGF)-mediated vascular hyperpermeability without altering VEGF receptor 2-dependent luteal angiogenesis in a rat ovarian hyperstimulation model", Endocrinology, 147, pp.5400~5411 (2006)
- Hershko Klement, A., "hCG Triggering in ART : An Evolutionary Concept", Int. J. Mol. Sci, 18, pp.1075~ (2017)
- Kosaka, K., "Vascular endothelial growth factor production by circulating immune cells is elevated in ovarian hyperstimulation syndrome", Hum. Reprod, 22, pp.1647~1651 (2007)
- Augustin, H. G., "Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system", Nat. Rev. Mol. Cell. Biol, 10, pp.165~177 (2009)
- Eklund, L., "Angiopoietin signaling in the vasculature", Exp. Cell Res, 319, pp.1271~1280 (2013)
- Korhonen, J., "Enhanced expression of the tie receptor tyrosine kinase in endothelial cells during neovascularization", Blood, 80, pp.2548~2555 (1992)
- Partanen, J., "A novel endothelial cell surface receptor tyrosine kinase with extracellular epidermal growth factor homology domains", Mol. Cell. Biol, 12, pp.1698~1707 (1992)
- Maisonpierre, P. C., "Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis", Science, 277, pp.55~60 (1997)
- Hazzard, T. M., "Vascular endothelial growth factor(VEGF)and angiopoietin regulation by gonadotrophin and steroids in macaque granulosa cells during the peri-ovulatory interval", Mol. Hum. Reprod, 5, pp.1115~1121 (1999)
- Yancopoulos, G. D., "Vascular-specific growth factors and blood vessel formation", Nature, 407, pp.242~248 (2000)
- Kfir, S., "Genomic profiling of bovine corpus luteum maturation", PLoS ONE, 13, pp.e0194456~ (2018)
- Ye, K., "Ang1", Tie2 induces cell proliferation and migration in human papillary thyroid carcinoma via the PI3K, Oncol. Lett, pp.2018, 15[DOI]
- Yin, J., "Angiopoietin : a novel neuroprotective", neurotrophic agent, 2019, pp.411, 177~184
- Quintana, R., "Inhibition of cyclooxygenase-2(COX-2)by meloxicam decreases the incidence of ovarian hyperstimulation syndrome in a rat model", Fertil. Steril, 90, pp.1511~1516 (2008)
- Wang, L., "Attenuated AMH signaling pathway plays an important role in the pathogenesis of ovarian hyperstimulation syndrome", Am. J. Transl. Res, 7, pp.1925~1938 (2015)
- Saharinen, P., "VEGF and angiopoietin signaling in tumor angiogenesis and metastasis", Trends Mol. Med, 17, pp.347~362 (2011)
- Shiojima, I., "Role of Akt signaling in vascular homeostasis and angiogenesis", Circ. Res, 90, pp.1243~1250 (2002)
- Abramov, Y., "Vascular endothelial growth factor plasma levels correlate to the clinical picture in severe ovarian hyperstimulation syndrome", Fertil. Steril, 67, pp.261~265 (1997)
- Gómez, R., "Administration of moderate and high doses of gonadotropins to female rats increases ovarian vascular endothelial growth factor(VEGF)and VEGF receptor-2 expression that is associated to vascular hyperpermeability", Biol. Reprod, 68, pp.2164~2171 (2003)
- Espey, L. L., "Induction of early growth response protein-1 gene expression in the rat ovary in response to an ovulatory dose of human chorionic gonadotropin", Endocrinology, 141, pp.2385~2391 (2000)
- Sayasith, K., "Characterization of bovine early growth response factor-1 and its gonadotropin-dependent regulation in ovarian follicles prior to ovulation", J. Mol. Endocrinol, 37, pp.239~250 (2006)
- Blaschke, F., "Egr-1 is a major vascular pathogenic transcription factor in atherosclerosis and restenosis", Rev. Endocr. Metab. Disord, 5, pp.249~254 (2004)
- Khachigian, L. M., "Early growth response-1 in the pathogenesis of cardiovascular disease", J. Mol. Med, 94, pp.747~753 (2016)
- Blumenfeld, Z., "The ovarian hyperstimulation syndrome", Vitam. Horm, 107, pp.423~451 (2018)
- Eskew, A. M., "Ovarian hyperstimulation syndrome management strategies : where are we going?", Min. Endocrinol, 43, pp.50~56 (2018)
- Manning, B. D., "AKT", PKB signaling: navigating the network, 2017, pp.169, 381~405
- Puri, M. C., "The receptor tyrosine kinase TIE is required for integrity and survival of vascular endothelial cells", EMBO J, 14, pp.5884~5891 (1995)
- Korhonen, E. A., "Tie1 controls angiopoietin function in vascular remodeling and inflammation", J. Clin. Invest, 126, pp.3495~3510 (2016)
- Ohba, T., "Ovarian hyperstimulation syndrome-model rats; the manifestation and clinical implication", Mol. Cell. Endocrinol, 202, pp.47~52 (2003)
- Li, T. T., "Friend or foe, the role of EGR-1 in cancer", Med. Oncol, 37, pp.7~ (2019)
- Siddappa, D., "Effect of the transient pharmacological inhibition of Mapk3", 1pathway on ovulation in mice, 2015, pp.10, e0119387~
- Zeng, C., "The effect of luteal GnRH antagonist on moderate and severe early ovarian hyperstimulation syndrome during in vitro fertilization treatment: a prospective cohort study", Arch. Gynecol. Obstet, 300, pp.223~233 (2019)